Table 3.
Univariate analysis for OS in EOC patients with FIGO stage IV with isolated NLNMs metastasis
| Variables | Death | Survival | Log rank p-value | |
|---|---|---|---|---|
| Age | ≤ 60 | 10 | 10 | 0.061 |
| > 60 | 0 | 4 | ||
| CA125 | < 600U/ml | 3 | 7 | 0.491 |
| ≥ 600U/ml | 7 | 7 | ||
| Ascites | No | 4 | 4 | 0.369 |
| < 500 ml | 4 | 10 | ||
| ≥ 500 ml | 2 | 0 | ||
| RD | R0 | 2 | 11 | 0.001 |
| R1/R2 | 7 | 3 | ||
| Surgery | IDS | 8 | 13 | 0.395 |
| PDS | 1 | 1 | ||
| NLNM size | ≤ 2 cm | 8 | 9 | 0.563 |
| > 2 cm | 2 | 5 | ||
| BRAC gene testing | BRCA mutant | 2 | 3 | 0.654 |
| BRCA wild-type/BRCA status unknown | 8 | 11 | ||
| Sites of first recurrence | lymph nodes | 1 | 3 | 0.012 |
| Abdomen or other distant sites(lung,brain,bone,…) | 9 | 2 | ||
| Maintenance therapy | Not obtain PARPi maintenance therapy | 9 | 9 | 0.135 |
| Obtain PARPi maintenance therapy | 1 | 5 | ||